{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T19:56:25Z","timestamp":1680724585214},"reference-count":13,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.3109\/10428194.2011.552140","type":"journal-article","created":{"date-parts":[[2011,1,28]],"date-time":"2011-01-28T01:32:41Z","timestamp":1296178361000},"page":"351-352","source":"Crossref","is-referenced-by-count":1,"title":["Chlorambucil in indolent mantle cell lymphoma \u2013 just another old drug for a new disease?"],"prefix":"10.1080","volume":"52","author":[{"given":"Martin","family":"Dreyling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Polliack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Tadmor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2011,1,27]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","unstructured":"Dreyling M, Hiddemann W: Current treatment standards and emerging strategies in mantle cell lymphoma. American Society of Hematology Education Program Book Hematology 2009: 542\u2013554.","DOI":"10.1182\/asheducation-2009.1.542"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3419"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1975.tb00911.x"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1961.tb00321.x"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197402)33:2<555::AID-CNCR2820330234>3.0.CO;2-I"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1326"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206185"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04586.x"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.534518"},{"issue":"21","key":"CIT0012","volume":"116","author":"Olivier Hermine","journal-title":"Blood"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6121"},{"key":"CIT0014","doi-asserted-by":"crossref","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustin plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL ASH 2009, #405.","DOI":"10.1182\/blood.V114.22.405.405"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/10428194.2011.552140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T02:34:31Z","timestamp":1592274871000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.3109\/10428194.2011.552140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,27]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,2,16]]},"published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.3109\/10428194.2011.552140"],"URL":"https:\/\/doi.org\/10.3109\/10428194.2011.552140","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,27]]}}}